JP2010539981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539981A5 JP2010539981A5 JP2010528054A JP2010528054A JP2010539981A5 JP 2010539981 A5 JP2010539981 A5 JP 2010539981A5 JP 2010528054 A JP2010528054 A JP 2010528054A JP 2010528054 A JP2010528054 A JP 2010528054A JP 2010539981 A5 JP2010539981 A5 JP 2010539981A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- variable region
- seq
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 25
- 102000003735 Mesothelin Human genes 0.000 claims description 18
- 108090000015 Mesothelin Proteins 0.000 claims description 18
- 206010033128 Ovarian cancer Diseases 0.000 claims description 17
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 206010027406 Mesothelioma Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 101710112752 Cytotoxin Proteins 0.000 claims description 7
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 7
- 239000002619 cytotoxin Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 6
- 230000002357 endometrial effect Effects 0.000 claims description 6
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 6
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims description 5
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 5
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 5
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims description 5
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims description 5
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims description 5
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000030427 mucinous ovarian cancer Diseases 0.000 claims description 5
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims description 5
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 101150000931 L6 gene Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 201000008274 breast adenocarcinoma Diseases 0.000 claims description 4
- 230000003013 cytotoxicity Effects 0.000 claims description 4
- 231100000135 cytotoxicity Toxicity 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 3
- 108010008629 CA-125 Antigen Proteins 0.000 claims description 2
- 102000007269 CA-125 Antigen Human genes 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000004712 monophosphates Chemical class 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 13
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 8
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 8
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 8
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000018463 endometrial serous adenocarcinoma Diseases 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97662607P | 2007-10-01 | 2007-10-01 | |
| US60/976,626 | 2007-10-01 | ||
| US99169207P | 2007-11-30 | 2007-11-30 | |
| US60/991,692 | 2007-11-30 | ||
| US7739708P | 2008-07-01 | 2008-07-01 | |
| US61/077,397 | 2008-07-01 | ||
| PCT/US2008/078123 WO2009045957A1 (en) | 2007-10-01 | 2008-09-29 | Human antibodies that bind mesothelin, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539981A JP2010539981A (ja) | 2010-12-24 |
| JP2010539981A5 true JP2010539981A5 (https=) | 2011-08-25 |
| JP5535074B2 JP5535074B2 (ja) | 2014-07-02 |
Family
ID=40526631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528054A Expired - Fee Related JP5535074B2 (ja) | 2007-10-01 | 2008-09-29 | メソテリンに結合するヒト抗体およびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US8268970B2 (https=) |
| EP (1) | EP2195017B1 (https=) |
| JP (1) | JP5535074B2 (https=) |
| KR (2) | KR101554753B1 (https=) |
| CN (1) | CN101951946B (https=) |
| AR (1) | AR068590A1 (https=) |
| AU (1) | AU2008308956B2 (https=) |
| BR (1) | BRPI0816014A8 (https=) |
| CA (1) | CA2700860C (https=) |
| CL (1) | CL2008002923A1 (https=) |
| CO (1) | CO6300960A2 (https=) |
| CY (1) | CY1116036T1 (https=) |
| DK (1) | DK2195017T3 (https=) |
| EA (1) | EA018396B1 (https=) |
| ES (1) | ES2526355T3 (https=) |
| HR (1) | HRP20150074T1 (https=) |
| IL (2) | IL204615A (https=) |
| MX (1) | MX2010003581A (https=) |
| NZ (1) | NZ584633A (https=) |
| PL (1) | PL2195017T3 (https=) |
| PT (1) | PT2195017E (https=) |
| RS (1) | RS53760B1 (https=) |
| SI (1) | SI2195017T1 (https=) |
| TW (1) | TWI446922B (https=) |
| WO (1) | WO2009045957A1 (https=) |
| ZA (1) | ZA201002313B (https=) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| CA2700860C (en) * | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| EP3103814A1 (en) * | 2007-11-26 | 2016-12-14 | Bayer Intellectual Property GmbH | Anti-mesothelin antibodies and uses therefor |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| PE20141114A1 (es) * | 2010-12-20 | 2014-09-15 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| KR102023496B1 (ko) | 2011-04-21 | 2019-09-20 | 시애틀 지네틱스, 인크. | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| KR101660146B1 (ko) | 2012-02-13 | 2016-09-26 | 브리스톨-마이어스 스큅 컴퍼니 | 에네디인 화합물, 그의 접합체, 및 그에 대한 용도 및 방법 |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| US9409992B2 (en) * | 2012-08-21 | 2016-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
| CN104955845B (zh) * | 2012-09-27 | 2018-11-16 | 美国政府(由卫生和人类服务部的部长所代表) | 间皮素抗体和引起有效的抗肿瘤活性的方法 |
| RS56169B1 (sr) | 2013-02-14 | 2017-11-30 | Bristol Myers Squibb Co | Jedinjenja tubulisina, metode pripreme i primena |
| WO2014146575A1 (en) | 2013-03-19 | 2014-09-25 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
| KR20160068738A (ko) | 2013-08-14 | 2016-06-15 | 윌리엄 마쉬 라이스 유니버시티 | 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도 |
| CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| ES2928000T3 (es) * | 2014-06-06 | 2022-11-14 | Memorial Sloan Kettering Cancer Center | Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos |
| PT3151921T (pt) | 2014-06-06 | 2019-11-21 | Bristol Myers Squibb Co | Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos |
| US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| JP6668345B2 (ja) | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| CN107207594B (zh) | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
| JP6676058B2 (ja) | 2015-01-14 | 2020-04-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
| TW201632531A (zh) | 2015-01-14 | 2016-09-16 | 必治妥美雅史谷比公司 | 苯二氮呯二聚物，其結合物及製造與使用方法 |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CN107406496A (zh) | 2015-03-10 | 2017-11-28 | 百时美施贵宝公司 | 可通过转谷氨酰胺酶缀合的抗体和由其制备的缀合物 |
| TN2017000440A1 (en) | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| CN106467573B (zh) * | 2015-08-21 | 2021-05-25 | 佧珐药业有限公司 | 抗间皮素全人抗体以及靶向间皮素的免疫效应细胞 |
| KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| BR112018010172A2 (pt) | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| AU2016377371A1 (en) | 2015-12-21 | 2018-08-09 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
| EP3393504B1 (en) | 2015-12-22 | 2025-09-24 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| AU2016382512A1 (en) | 2015-12-30 | 2018-07-12 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| AU2017225733A1 (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore |
| KR20230038311A (ko) | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| MY209117A (en) | 2016-04-15 | 2025-06-23 | Novartis Ag | Compositions and methods for selective protein expression |
| WO2017190148A1 (en) * | 2016-04-29 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| KR20190005924A (ko) | 2016-05-10 | 2019-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 향상된 안정성을 갖는 튜부리신 유사체의 항체-약물 접합체 |
| WO2017201502A1 (en) | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| US20190161542A1 (en) | 2016-08-01 | 2019-05-30 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| CN109641911B (zh) | 2016-08-19 | 2023-02-21 | 百时美施贵宝公司 | seco-环丙吡咯并吲哚化合物和其抗体-药物缀合物以及制备和使用方法 |
| WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
| WO2018094282A1 (en) * | 2016-11-18 | 2018-05-24 | The Regents Of The University Of California | Engineered antibodies and uses thereof |
| EP3548515B1 (en) | 2016-12-01 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| SI3579883T1 (sl) | 2017-02-08 | 2021-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
| CN110506057B (zh) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
| KR102775647B1 (ko) | 2017-03-31 | 2025-03-06 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| CN110869392A (zh) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| IL270596B2 (en) | 2017-05-25 | 2026-01-01 | Bristol Myers Squibb Co | Antibodies containing heavy constant regions are adapted for use in cancer therapy |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US20200239577A1 (en) | 2017-10-15 | 2020-07-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
| KR101966362B1 (ko) | 2017-10-20 | 2019-04-05 | 주식회사 녹십자 | 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| WO2019133639A2 (en) * | 2017-12-26 | 2019-07-04 | The Regents Of The University Of California | Human antibodies that bind and are internalized by mesothelioma and other cancer cells |
| PE20210665A1 (es) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | Anticuerpos contra mica y/o micb y sus usos |
| EP3774911A1 (en) | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US20210147570A1 (en) | 2018-04-12 | 2021-05-20 | Bristol-Myers Squibb Company | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| CN112188902A (zh) | 2018-05-29 | 2021-01-05 | 百时美施贵宝公司 | 用于前药和缀合物的经修饰的自消灭部分以及使用和制造方法 |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3806889A4 (en) * | 2018-06-18 | 2022-07-13 | Anwita Biosciences, Inc. | CYTOKI FUSION PROTEINS AND USES THEREOF |
| US11020490B2 (en) | 2018-06-22 | 2021-06-01 | Bristol-Myers Squibb Company | Antibody-drug conjugate with a tubulysin analog warhead having a stabilized acetate group in the TUV subunit |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN110746508B (zh) * | 2018-07-23 | 2023-04-14 | 上海细胞治疗集团有限公司 | 特异性结合间皮素的单克隆抗体及嵌合抗原受体 |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| ES2943474T3 (es) | 2018-11-30 | 2023-06-13 | Bristol Myers Squibb Co | Anticuerpo que comprende una extensión carboxiterminal de una cadena ligera que contiene glutamina, conjugados del mismo, y métodos y usos |
| KR20210102334A (ko) | 2018-12-12 | 2021-08-19 | 브리스톨-마이어스 스큅 컴퍼니 | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CN109705219B (zh) * | 2019-01-08 | 2020-11-13 | 上海霖科生物科技有限公司 | 与间皮素结合的单克隆抗体及其制备方法 |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| CN110698562B (zh) * | 2019-10-31 | 2022-10-25 | 浙江蓝盾药业有限公司 | 抗人msln单克隆抗体 |
| JP7727628B2 (ja) | 2019-12-03 | 2025-08-21 | アラマー バイオサイエンシーズ， インク． | 核酸結合免疫サンドイッチアッセイ（ｎｕｌｉｓａ） |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| MX2022007688A (es) | 2019-12-20 | 2022-07-19 | Amgen Inc | Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos. |
| CN113698492B (zh) * | 2020-05-22 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| SMT202500208T1 (it) | 2020-12-28 | 2025-07-22 | Bristol Myers Squibb Co | Composizioni anticorpali e metodi per il loro uso |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| AU2022222688B2 (en) * | 2021-02-16 | 2025-11-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to mesothelin polypeptides |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| KR102860436B1 (ko) * | 2021-06-30 | 2025-09-19 | (주)이노베이션바이오 | 메소텔린 특이적 항체 및 이의 용도 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| AU2022407541A1 (en) * | 2021-12-10 | 2024-06-13 | Merck Sharp & Dohme Llc | Human mesothelin binders |
| WO2023115528A1 (en) * | 2021-12-24 | 2023-06-29 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against mesothelin and uses thereof |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| EP4531916A1 (en) | 2022-06-02 | 2025-04-09 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025188693A1 (en) | 2024-03-05 | 2025-09-12 | Bristol-Myers Squibb Company | Bicyclic tlr7 agonists and uses thereof |
| WO2025188694A1 (en) | 2024-03-05 | 2025-09-12 | Bristol-Myers Squibb Company | Tricyclic tlr7 agonists and uses thereof |
| WO2025247171A1 (en) * | 2024-05-27 | 2025-12-04 | Harbour Antibodies Bv | Anti-mesothelin antibodies |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4978757A (en) | 1984-02-21 | 1990-12-18 | The Upjohn Company | 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds |
| US4912227A (en) | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
| US5332837A (en) | 1986-12-19 | 1994-07-26 | The Upjohn Company | CC-1065 analogs |
| US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
| JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| AU648313B2 (en) | 1990-04-25 | 1994-04-21 | Pharmacia & Upjohn Company | Novel CC-1065 analogs |
| EP0554356B1 (en) | 1990-10-12 | 1998-09-16 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | A monoclonal antibody |
| JPH0597853A (ja) | 1991-10-07 | 1993-04-20 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ−８９誘導体の臭化水素酸塩 |
| JP3328341B2 (ja) | 1991-12-27 | 2002-09-24 | 中外製薬株式会社 | 新規な巨核球増幅因子 |
| IL107366A (en) | 1992-10-23 | 2003-03-12 | Chugai Pharmaceutical Co Ltd | Genes coding for megakaryocyte potentiator |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| CA2165819C (en) | 1994-04-22 | 2005-12-27 | Nobuyoshi Amishiro | Dc-89 derivatives |
| JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
| FI971278L (fi) | 1994-09-30 | 1997-05-27 | Kyowa Hakko Kogyo Kk | Kasvainten vastaisia aineita |
| WO1997007671A1 (en) * | 1995-08-29 | 1997-03-06 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for constructing the same |
| US7375183B1 (en) | 1996-01-05 | 2008-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof |
| DE69726404T2 (de) | 1996-01-05 | 2004-09-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mesothelinantigen, verfahren und testsatz zur targetierung |
| US6809184B1 (en) | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| ATE317437T1 (de) * | 1997-12-01 | 2006-02-15 | Us Gov Health & Human Serv | Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung |
| DE60028361T2 (de) | 1999-02-26 | 2007-05-10 | Pacific Northwest Research Institute, Seattle | Verfahren und zusammensetzungen zur karzinomdiagnose |
| US6770445B1 (en) | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
| DK1180123T3 (da) | 1999-05-27 | 2008-10-13 | Us Gov Health & Human Serv | Immunkonjugater, der har höj bindingsaffinitet |
| US7288390B2 (en) * | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7129261B2 (en) | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| US7125663B2 (en) | 2001-06-13 | 2006-10-24 | Millenium Pharmaceuticals, Inc. | Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer |
| EP1517998A2 (en) | 2001-06-18 | 2005-03-30 | EOS Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| HUP0600342A3 (en) * | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| CN103540600B (zh) | 2003-01-22 | 2017-12-01 | 罗氏格黎卡特股份公司 | 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途 |
| CN1761746B (zh) * | 2003-01-22 | 2016-03-23 | 罗氏格黎卡特股份公司 | 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途 |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| JP2007525971A (ja) | 2003-08-05 | 2007-09-13 | モルフォテック、インク． | 癌に関連する変異体細胞表面分子 |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| RS53984B1 (sr) * | 2003-12-10 | 2015-10-30 | E. R. Squibb & Sons L.L.C. | Ip-10 antitela i njihove upotrebe |
| US20050266008A1 (en) * | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| CA2600505C (en) * | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| WO2006124641A2 (en) * | 2005-05-12 | 2006-11-23 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Anti-mesothelin antibodies useful for immunological assays |
| BRPI0617546A2 (pt) | 2005-09-26 | 2011-07-26 | Medarex Inc | conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto |
| SI1940789T1 (sl) | 2005-10-26 | 2012-03-30 | Medarex Inc | Postopki in spojine za pripravo cc analogov |
| EP1942944A2 (en) | 2005-10-31 | 2008-07-16 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
| CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| EP1994000B1 (en) | 2006-02-02 | 2017-08-23 | Syntarga B.V. | Water-soluble cc-1065 analogs and their conjugates |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | 梅達雷克斯有限責任公司 | 化學鏈接劑與可裂解基質以及其之綴合物 |
| CN101012280A (zh) * | 2007-02-07 | 2007-08-08 | 吴小华 | 抗人可溶性间皮素相关蛋白单克隆抗体的制备方法 |
| CA2678514A1 (en) | 2007-02-21 | 2008-08-28 | Medarex, Inc. | Chemical linkers with single amino acids and conjugates thereof |
| CA2700860C (en) * | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| EP3103814A1 (en) * | 2007-11-26 | 2016-12-14 | Bayer Intellectual Property GmbH | Anti-mesothelin antibodies and uses therefor |
-
2008
- 2008-09-29 CA CA2700860A patent/CA2700860C/en not_active Expired - Fee Related
- 2008-09-29 RS RS20150044A patent/RS53760B1/sr unknown
- 2008-09-29 NZ NZ584633A patent/NZ584633A/en not_active IP Right Cessation
- 2008-09-29 HR HRP20150074AT patent/HRP20150074T1/hr unknown
- 2008-09-29 EA EA201070412A patent/EA018396B1/ru not_active IP Right Cessation
- 2008-09-29 BR BRPI0816014A patent/BRPI0816014A8/pt not_active Application Discontinuation
- 2008-09-29 ES ES08836490.6T patent/ES2526355T3/es active Active
- 2008-09-29 PL PL08836490T patent/PL2195017T3/pl unknown
- 2008-09-29 EP EP08836490.6A patent/EP2195017B1/en active Active
- 2008-09-29 AU AU2008308956A patent/AU2008308956B2/en not_active Ceased
- 2008-09-29 CN CN200880110024.5A patent/CN101951946B/zh not_active Expired - Fee Related
- 2008-09-29 KR KR1020107009426A patent/KR101554753B1/ko not_active Expired - Fee Related
- 2008-09-29 DK DK08836490.6T patent/DK2195017T3/en active
- 2008-09-29 WO PCT/US2008/078123 patent/WO2009045957A1/en not_active Ceased
- 2008-09-29 JP JP2010528054A patent/JP5535074B2/ja not_active Expired - Fee Related
- 2008-09-29 KR KR1020157008793A patent/KR101554848B1/ko not_active Expired - Fee Related
- 2008-09-29 SI SI200831341T patent/SI2195017T1/sl unknown
- 2008-09-29 US US12/681,215 patent/US8268970B2/en active Active
- 2008-09-29 PT PT88364906T patent/PT2195017E/pt unknown
- 2008-09-29 MX MX2010003581A patent/MX2010003581A/es active IP Right Grant
- 2008-09-30 CL CL2008002923A patent/CL2008002923A1/es unknown
- 2008-09-30 AR ARP080104267A patent/AR068590A1/es unknown
- 2008-10-01 TW TW097137770A patent/TWI446922B/zh not_active IP Right Cessation
-
2010
- 2010-03-18 IL IL204615A patent/IL204615A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02313A patent/ZA201002313B/en unknown
- 2010-04-27 CO CO10049719A patent/CO6300960A2/es active IP Right Grant
-
2012
- 2012-08-16 US US13/587,500 patent/US8399623B2/en active Active
- 2012-08-16 US US13/587,644 patent/US8425904B2/en active Active
- 2012-08-16 US US13/587,572 patent/US8383779B2/en active Active
-
2013
- 2013-03-14 US US13/827,946 patent/US20130190481A1/en not_active Abandoned
-
2015
- 2015-01-21 CY CY20151100062T patent/CY1116036T1/el unknown
- 2015-12-28 IL IL243375A patent/IL243375B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539981A5 (https=) | ||
| AU2019320336B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| BR112021011014A2 (pt) | Anticorpos anti-claudina e usos destes | |
| CN113271942A (zh) | 抗体-药物缀合物与parp抑制剂的组合 | |
| JP7769032B2 (ja) | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| TW201920078A (zh) | 抗體－藥物結合物之新穎製造方法 | |
| JPWO2018066626A1 (ja) | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 | |
| JPWO2021177438A5 (https=) | ||
| BR112020024061A2 (pt) | agente terapêutico para câncer com her2 mutado | |
| EP4164388A1 (en) | Anti-human neurotensin receptor 1 antibody and use thereof | |
| EP4721766A1 (en) | Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor | |
| JP2025540063A (ja) | 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用 | |
| BR122024023393A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica | |
| BR122024023391A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica | |
| WO2024210162A1 (ja) | 抗ｍｕｃ１抗体－薬物コンジュゲート投与による薬剤低感受性がんの治療方法 | |
| HK40130006A (zh) | 通过施用抗her2抗体-药物缀合物治疗her2突变的癌 | |
| HK40043732A (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| EA050611B1 (ru) | Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина | |
| BR122023026672A2 (pt) | Uso de um conjugado de anticorpo-fármaco | |
| BR122023026675A2 (pt) | Uso de um conjugado de anticorpo-fármaco | |
| BR122023026673A2 (pt) | Uso de um conjugado de anticorpo-fármaco | |
| BR122023026671A2 (pt) | Uso de um conjugado de anticorpo-fármaco | |
| EA046932B1 (ru) | Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство | |
| EA053135B1 (ru) | Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство | |
| HK40040246A (en) | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate |